Use of Biologics During Pregnancy Among Patients With Autoimmune Conditions
Authors' conclusion
In this cohort study, a decline in the use of biologics for autoimmune disease was observed during the pregnancy period that rebounded only partially thereafter.
Study context
- Population
- Commercially insured pregnant patients aged 16 to 55 years with an autoimmune condition and biologic use 6 months before conception, US MarketScan, 2011–2022median age 32 years
- Participants
- 6,131 participants
- Exposure
- Biologic use during pregnancy across autoimmune conditions
- Crohn diseasen = 1,372
- RAn = 1,295reference
- Outcome
- Proportion of patients using biologics during pregnancy; association between underlying autoimmune disease and biologic use
Methodological detailsadministrative claims database, multivariable logistic regression
- Administrative claims database
- Multivariable logistic regression
Main finding
As reported in the abstract
Biologic use at least once during pregnancy
All patients
4393
71.6%; 95% CI, 70.5%–72.8%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Biologic use during pregnancy by autoimmune conditionCrohn diseasevs RAMultivariable logistic regression | 7.88 (5.93–10.47) | |
| Biologic use during pregnancy by autoimmune conditionUlcerative colitisvs RAMultivariable logistic regression | 5.35 (3.73–7.66) | |
| Biologic use during pregnancy by autoimmune conditionPsoriasis or PsAvs RAMultivariable logistic regression | 0.65 (0.52–0.80) | |
| 0.050.21520Odds ratio (log scale) |
Biologic use by trimester, pregnancies with live birth
- First trimester
- 2981 (68.6% [95% CI, 67.2%-70.0%])
- Second trimester
- 2555 (58.8% [95% CI, 57.3%-60.3%])
- Third trimester
- 2113 (48.6% [95% CI, 47.1%-50.1%])
- Post partum
- 3350 (77.1% [95% CI, 75.8%-78.3%])
Original publication
Use of Biologics During Pregnancy Among Patients With Autoimmune Conditions. JAMA Netw Open. Published 1 May 2025. doi:10. 1001/ jamanetworkopen. 2025. 10504
Composed by AI from the published abstract and checked against it. How Briefs are made →